

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>CELGENE CORP /DE/</u> (Last) (First) (Middle) <u>CELGENE CORPORATION</u> <u>86 MORRIS AVENUE</u> (Street) <u>SUMMIT NJ 07901</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>AGIOS PHARMACEUTICALS, INC. [AGIO]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>11/12/2019</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/12/2019		P		403,225	A	\$31	1,777,824	D	
Common Stock								624,575	I	See footnote ⁽¹⁾
Common Stock								4,010,926	I	See footnote ⁽²⁾
Common Stock								708,333	I	See footnote ⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)					

1. Name and Address of Reporting Person*
CELGENE CORP /DE/
 (Last) (First) (Middle)
CELGENE CORPORATION
86 MORRIS AVENUE
 (Street)
SUMMIT NJ 07901
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Celgene European Investment Co LLC
 (Last) (First) (Middle)
86 MORRIS AVENUE
 (Street)
SUMMIT NJ 07901
 (City) (State) (Zip)

1. Name and Address of Reporting Person*

[Celgene Switzerland LLC](#)

(Last) (First) (Middle)

AON HOUSE
30 WOODBOURNE AVENUE

(Street)

PEMBROKE D0 HM 08

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[Celgene Alpine Investment Co., LLC](#)

(Last) (First) (Middle)

86 MORRIS AVENUE

(Street)

SUMMIT X1 07901

(City) (State) (Zip)

Explanation of Responses:

- Owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene and the other reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
- Owned directly by Celgene European Investment Company LLC, a wholly-owned subsidiary of Celgene. Celgene and the other reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
- Owned directly by Celgene Alpine Investment Co., LLC, a wholly-owned subsidiary of Celgene. Celgene and the other reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

[/s/ Kevin Mello, Manager,](#)
[Celgene European Investment](#) [11/14/2019](#)
[Company LLC](#)

[/s/ Kevin Mello, Manager,](#) [11/14/2019](#)
[Celgene Switzerland LLC](#)

[/s/ Kevin Mello, Manager,](#) [11/14/2019](#)
[Celgene Alpine Investment](#)
[Co., LLC](#)

[/s/ David V. Elkins, Executive](#)
[Vice President & Chief](#) [11/14/2019](#)
[Financial Officer, Celgene](#)
[Corporation](#)

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.